Synthetic Cannabinoids

A systematic review of Safety and effectiveness of cannabinoids for the treatment of neuropsychiatric symptoms in dementia

A 2019 literature review summarizes the finding on using THC and CBD on patients with dementia. Researchers found that Dronabinol and THC were associated with significant improvements in a range of psychiatric scores. Interestingly, cannabis products showed the most promising results in patients whose symptoms were previously unmanageable or resistant to other treatments.

View this review (yellow link) or download:

This paper is also stored here:    http://bit.ly/2IWFA8R     inside the CED Foundation Archive

To explore related information, click the keywords below:

Benjamin Caplan, MDA systematic review of Safety and effectiveness of cannabinoids for the treatment of neuropsychiatric symptoms in dementia
read more

Cannabinoids + opioid pain relief: subjective effects in healthy humans

Human study finds that, when taken with opioids, dronabinol (THC) may increase impairment and decrease, or not affect, pain relief. Researchers conclude that THC might NOT protect the body from the adverse effects of opioids. However, the study examined only 10 participants, and such a small sample size should give pause to the validity and applicability of the findings. 

View this review (yellow link) or download:

This paper is also stored here:    http://bit.ly/2IHJuSO     inside the CED Foundation Archive

To explore related information, click the keywords below:

Benjamin Caplan, MDCannabinoids + opioid pain relief: subjective effects in healthy humans
read more

THC Has Potential for Treating Agitation in Alzheimer’s Disease

In a crossover trial of 39 patients with Alzheimer’s disease, treatment with nabilone (a synthetic THC analog) was associated with significant improvement in agitation and, remarkably, cognition. Further studies should examine the effects of both THC and CBD in patients with Alzheimer’s disease because anxiety is common in dementia and may exacerbate agitation. 

View this review (yellow link) or download:

This paper is also stored here:   http://bit.ly/2IH2BfX      inside the CED Foundation Archive

To explore related information, click the keywords below:

Benjamin Caplan, MDTHC Has Potential for Treating Agitation in Alzheimer’s Disease
read more

Dronabinol: antileukemic activity in acute lymphoblastic and myeloid leukemia with lymphoid differentiation patterns

Study provides rigorous data to support clinical evaluation of THC as a low-toxic therapy option in acute leukemia patients. In related work, full-spectrum, natural derivatives of cannabis may work more effectively than their pharmaceutical counterparts.

View this review (yellow link) or download:

This paper is also stored here:    http://bit.ly/2KVVXnD     inside the CED Foundation Archive

To explore related information, click the keywords below:

Benjamin Caplan, MDDronabinol: antileukemic activity in acute lymphoblastic and myeloid leukemia with lymphoid differentiation patterns
read more

Synthetic Cannabinoids Provide Evidence for Targeting Cannabinoid Receptors in the Treatment of Autoimmune Diseases

Pharmaceutical Cannabis Derivatives Help Discover their Receptors and Functions for Autoimmune Illnesses

A recent study conducted by Michigan State University exposed the potential for cannabinoid receptor 2 (CB2) to target the treatment of inflammatory conditions. Elevated levels of plasmacytoid dendritic cells (pCD, a type of cell in the immune system) contribute to chronic inflammation in autoimmune diseases, such as Rheumatoid Arthritis. Researchers found that synthetic CB2 agonists reported comparable benefits to THC, but minimized the cerebral effects as the psychotropic activity is mediated by cannabinoid receptor 1 (CB1). This evidence demonstrates the potential benefits of CB2-targeted treatment for inflammatory conditions. Unfortunately, there are serious concerns about the misuse of some synthetic cannabinoids, so there is still a missing bridge, in products and public education, between these research products and potential therapeutic pharmaceuticals, down the road.

View this review (yellow link) or download:

This paper is also stored here:  http://bit.ly/2HZ6cWb  inside the CED Foundation Archive

To explore related information, click keywords:

Benjamin Caplan, MDSynthetic Cannabinoids Provide Evidence for Targeting Cannabinoid Receptors in the Treatment of Autoimmune Diseases
read more

Producing the ‘problem’ of new psychoactive substances (NPS) in English prisons

The use of synthetic cannabinoids in English prisons is currently considered a “law, order and control” problem, with associated regulation and penalties. There is a clear and problematic disconnect between prison administrators and users. Resources for education, training and work opportunities are missing.

For the full review:

Benjamin Caplan, MDProducing the ‘problem’ of new psychoactive substances (NPS) in English prisons
read more